OpenLB
Open Library of Bioscience
Advanced Search
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
Jul, 2021;72 (7): 619-632.

[Management of malignant adnexal neoplasms of the skin].

Pia Nagel, Verena Müller, Jochen Utikal
Author Information
  1. Pia Nagel: Klinische Kooperationseinheit für Dermatoonkologie des Deutschen Krebsforschungszentrums (DKFZ) Heidelberg, Mannheim, Deutschland.
  2. Verena Müller: Klinische Kooperationseinheit für Dermatoonkologie des Deutschen Krebsforschungszentrums (DKFZ) Heidelberg, Mannheim, Deutschland.
  3. Jochen Utikal: Klinische Kooperationseinheit für Dermatoonkologie des Deutschen Krebsforschungszentrums (DKFZ) Heidelberg, Mannheim, Deutschland. jochen.utikal@umm.de.
PMID: 34137901 DOI: 10.1007/s00105-021-04829-x

Abstract

Malignant adnexal neoplasms of the skin are a heterogeneous group of rare malignancies with eccrine, apocrine, sebaceous and follicular differentiation. Essential clinical practice recommendations for the overall management of these cancers are presented. Moreover, specific evidence-based findings according to diagnosis, therapy and follow-up of porocarcinoma, sebaceous carcinoma and microcystic adnexcarcinoma will be explained.

Keywords

Histopathology Malignancy Microcystic adnexal carcinoma Porocarcinoma Sebaceous gland neoplasms

References

  1. Weltgesundheitsorganisation (2018) WHO classification of skin tumours. International Agency for Research on Cancer, Lyon
  2. Stam H, Lohuis PJ, Zupan-Kajcovski B et al (2013) Increasing incidence and survival of a rare skin cancer in the Netherlands. A population-based study of 2,220 cases of skin adnexal carcinoma. J Surg Oncol 107:822–827 [PMID: 23505050]
  3. Tanese K, Nakamura Y, Hirai I et al (2019) Updates on the systemic treatment of advanced non-melanoma skin cancer. Front Med 6:160
  4. Jandali DB, Ganti A, Al-Khudari S et al (2019) Prognostic factors and survival outcomes for head and neck cutaneous adnexal cancers. Am J Otolaryngol 40:110–114 [PMID: 30472120]
  5. Waqas O, Faisal M, Haider I et al (2017) Retrospective study of rare cutaneous malignant adnexal tumors of the head and neck in a tertiary care cancer hospital: a case series. J Med Case Rep 11:67 [PMID: 28284233]
  6. Abbate M, Zeitouni NC, Seyler M et al (2003) Clinical course, risk factors, and treatment of microcystic adnexal carcinoma: a short series report. Dermatol Surg 29:1035–1038 [PMID: 12974700]
  7. Blake PW, Bradford PT, Devesa SS et al (2010) Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study. Arch Dermatol 146:625–632 [PMID: 20566926]
  8. De Giorgi V, Salvati L, Barchielli A et al (2019) The burden of cutaneous adnexal carcinomas and the risk of associated squamous cell carcinoma: a population-based study. Br J Dermatol 180:565–573 [PMID: 30328107]
  9. Harwood CA, Mcgregor JM, Swale VJ et al (2003) High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol 48:401–408 [PMID: 12637920]
  10. Lanoy E, Dores GM, Madeleine MM et al (2009) Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS 23:385–393 [PMID: 19114864]
  11. Fueston JC, Gloster HM, Mutasim DF (2006) Primary cutaneous adenoid cystic carcinoma: a case report and literature review. Cutis 77:157–160 [PMID: 16610734]
  12. Rismiller K, Knackstedt TJ (2018) Aggressive digital papillary adenocarcinoma: population-based analysis of incidence, demographics, treatment, and outcomes. Dermatol Surg 44:911–917 [PMID: 29578881]
  13. Owen JL, Kibbi N, Worley B et al (2019) Sebaceous carcinoma: evidence-based clinical practice guidelines. Lancet Oncol 20:e699–e714 [PMID: 31797796]
  14. Worley B, Owen JL, Barker CA et al (2019) Evidence-based clinical practice guidelines for microcystic adnexal carcinoma: informed by a systematic review. JAMA Dermatol 155(9):1059–1068. https://doi.org/10.1001/jamadermatol.2019.1251 [DOI: 10.1001/jamadermatol.2019.1251]
  15. Alsaad KO, Obaidat NA, Ghazarian D (2007) Skin adnexal neoplasms-—part 1: an approach to tumours of the pilosebaceous unit. J Clin Pathol 60:129–144 [PMID: 16882696]
  16. Obaidat NA, Alsaad KO, Ghazarian D (2007) Skin adnexal neoplasms—part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol 60:145–159 [PMID: 16882695]
  17. Goyal A, Marghitu T, Goyal N et al (2020) Surgical management and lymph-node biopsy of rare malignant cutaneous adnexal carcinomas: a population-based analysis of 7591 patients. Arch Dermatol Res. https://doi.org/10.1007/s00403-020-02143-5
  18. Wittekind C (2020) TNM – Klassifikation maligner Tumoren. Wiley-VCH, Weinheim
  19. Martinez SR, Barr KL, Canter RJ (2011) Rare tumors through the looking glass: an examination of malignant cutaneous adnexal tumors. Arch Dermatol 147:1058–1062 [PMID: 21931043]
  20. Bernárdez C, Requena L (2018) Treatment of malignant cutaneous Adnexal neoplasms. Actas Dermosifiliogr 109:6–23 [PMID: 28988763]
  21. Belin E, Ezzedine K, Stanislas S et al (2011) Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. Br J Dermatol 165:985–989 [PMID: 21711331]
  22. Hardisson D, Linares MD, Cuevas-Santos J et al (2001) Pilomatrix carcinoma: a clinicopathologic study of six cases and review of the literature. Am J Dermatopathol 23:394–401 [PMID: 11801770]
  23. Lazar AJ, Calonje E, Grayson W et al (2005) Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. J Cutan Pathol 32:148–157 [PMID: 15606674]
  24. Kyriazanos ID, Stamos NP, Miliadis L et al (2011) Extra-mammary Paget’s disease of the perianal region: a review of the literature emphasizing the operative management technique. Surg Oncol 20:e61–e71 [PMID: 20884199]
  25. Chung PH, Leong JY, Voelzke BB (2019) Surgical experience with genital and perineal extramammary Paget’s disease. Urology 128:90–95 [PMID: 30902697]
  26. Wollina U, Goldman A, Bieneck A et al (2018) Surgical treatment for extramammary Paget’s disease. Curr Treat Options Oncol 19:27 [PMID: 29725859]
  27. Dokic Y, Nguyen QL, Orengo I (2020) Mohs micrographic surgery: a treatment method for many non-melanocytic skin cancers. Dermatol Online J 26(4):13030/qt8zr4f9n4
  28. Wang LS, Handorf EA, Wu H et al (2017) Surgery and adjuvant radiation for high-risk skin Adnexal carcinoma of the head and neck. Am J Clin Oncol 40:429–432 [PMID: 25599317]
  29. Snast I, Sharon E, Kaftory R et al (2020) Nonsurgical treatments for extramammary Paget disease: a systematic review and meta-analysis. Dermatology 236(6):493–499. https://doi.org/10.1159/000506832 [DOI: 10.1159/000506832]
  30. Nagasawa T, Hirata A, Niiyama S et al (2019) Successful treatment of porocarcinoma with maxacalcitol and imiquimod. Dermatol Ther 32:e12830 [PMID: 30659720]
  31. Jo JH, Ko HC, Jang HS et al (2005) Infiltrative trichilemmal carcinoma treated with 5 % imiquimod cream. Dermatol Surg 31:973–976 [PMID: 16042947]
  32. Borgognoni L, Pescitelli L, Gerlini G et al (2020) Efficacy of electrochemotherapy in the treatment of cutaneous melanoma metastases and rare non-melanoma skin cancer. Anticancer Res 40:6485–6492 [PMID: 33109587]
  33. Borgognoni L, Pescitelli L, Urso C et al (2014) A rare case of anal porocarcinoma treated by electrochemotherapy. Future Oncol 10:2429–2434 [PMID: 25525852]
  34. Ribero S, Baduel ES, Brizio M et al (2016) Metastatic sebaceous cell carcinoma, review of the literature and use of electrochemotherapy as possible new treatment modality. Radiol Oncol 50:308–312 [PMID: 27679547]
  35. Wakabayashi A, Tanese K, Yamamoto K et al (2010) Extraocular sebaceous carcinoma expressing oestrogen receptor alpha and human epidermal growth factor receptor 2. Clin Exp Dermatol 35:546–548 [PMID: 19874363]
  36. Tanese K, Wakabayashi A, Suzuki T et al (2010) Immunoexpression of human epidermal growth factor receptor‑2 in apocrine carcinoma arising in naevus sebaceous, case report. J Eur Acad Dermatol Venereol 24:360–362 [PMID: 19703100]
  37. Ohi Y, Kosuge H, Tanese K (2015) Case of syringomatous carcinoma: Positive immunohistochemical staining of c‑KIT and phosphorylated-extracellular signal-regulated kinase 1/2. J Dermatol 42:1191–1192 [PMID: 26282337]
  38. Hiatt KM, Pillow JL, Smoller BR (2004) Her‑2 expression in cutaneous eccrine and apocrine neoplasms. Mod Pathol 17:28–32 [PMID: 14631375]
  39. Duverger L, Osio A, Cribier B et al (2019) Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas. Cancer Immunol Immunother 68:951–960 [PMID: 30953116]
  40. Soni A, Bansal N, Kaushal V et al (2015) Current management approach to hidradenocarcinoma: a comprehensive review of the literature. Ecancermedicalscience 9:517 [PMID: 25815059]
  41. Johnson EP, Keyes J, Zayat V et al (2020) Malignant hidradenocarcinoma of the Axilla. Cureus 12:e7091 [PMID: 32226692]
  42. Robson A, Greene J, Ansari N et al (2001) Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol 25:710–720 [PMID: 11395548]
  43. Nazemi A, Higgins S, Swift R et al (2018) Eccrine porocarcinoma: new insights and a systematic review of the literature. Dermatol Surg 44:1247–1261 [PMID: 29894433]
  44. Herrmann JL, Allan A, Trapp KM et al (2014) Pilomatrix carcinoma: 13 new cases and review of the literature with emphasis on predictors of metastasis. J Am Acad Dermatol 71:38–43.e32 [PMID: 24739254]
  45. Leiter U, Heppt MV, Steeb T et al (2020) S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Kurzfassung, Teil 2: Epidemiologie, chirurgische und systemische Therapie des Plattenepithelkarzinoms, Nachsorge, Prävention und Berufskrankheit. J Dtsch Dermatol Ges 18:400–413 [PMID: 32291932]
  46. Mehregan AH, Hashimoto K, Rahbari H (1983) Eccrine adenocarcinoma. A clinicopathologic study of 35 cases. Arch Dermatol 119:104–114 [PMID: 6297408]
  47. Marone U, Caracò C, Anniciello AM et al (2011) Metastatic eccrine porocarcinoma: report of a case and review of the literature. World J Surg Oncol 9:32 [PMID: 21410982]
  48. Kurokawa M, Amano M, Miyaguni H et al (2001) Eccrine poromas in a patient with mycosis fungoides treated with electron beam therapy. Br J Dermatol 145:830–833 [PMID: 11736912]
  49. Shaw M, Mckee PH, Lowe D et al (1982) Malignant eccrine poroma: a study of twenty-seven cases. Br J Dermatol 107:675–680 [PMID: 6293528]
  50. Song SS, Wu LW, Hamman MS et al (2015) Mohs micrographic surgery for eccrine porocarcinoma: an update and review of the literature. Dermatol Surg 41:301–306 [PMID: 25742554]
  51. Snow SN, Reizner GT (1992) Eccrine porocarcinoma of the face. J Am Acad Dermatol 27:306–311 [PMID: 1325487]
  52. Ahn CS, Sangüeza OP (2019) Malignant sweat gland tumors. Hematol Oncol Clin North Am 33:53–71 [PMID: 30497677]
  53. Nguyen A, Nguyen AV (2014) Eccrine porocarcinoma: a report of 2 cases and review of the literature. Cutis 93:43–46 [PMID: 24505584]
  54. Tsunoda K, Onishi M, Maeda F et al (2019) Evaluation of sentinel lymph node biopsy for eccrine porocarcinoma. Acta Derm Venereol 99:691–692 [PMID: 30868172]
  55. Salih AM, Kakamad FH, Baba HO et al (2017) Porocarcinoma; presentation and management, a meta-analysis of 453 cases. Ann Med Surg 20:74–79
  56. Bogner PN, Fullen DR, Lowe L et al (2003) Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma. Cancer 97:2285–2289 [PMID: 12712485]
  57. Khaja M, Ashraf U, Mehershahi S et al (2019) Recurrent metastatic eccrine porocarcinoma: a case report and review of the literature. Am J Case Rep 20:179–183 [PMID: 30739904]
  58. Godillot C, Boulinguez S, Riffaud L et al (2018) Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy. Eur J Cancer 90:142–145 [PMID: 29233613]
  59. Lee KA, Cioni M, Robson A et al (2019) Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab. BMJ Case Rep 12(9):e228917. https://doi.org/10.1136/bcr-2018-228917 [DOI: 10.1136/bcr-2018-228917]
  60. Sa HS, Rubin ML, Xu S et al (2019) Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients. Br J Ophthalmol 103:980–984 [PMID: 30131380]
  61. Roberts ME, Riegert-Johnson DL, Thomas BC et al (2014) A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med 16:711–716 [PMID: 24603434]
  62. Kibbi N, Worley B, Owen JL et al (2020) Sebaceous carcinoma: controversies and their evidence for clinical practice. Arch Dermatol Res 312:25–31 [PMID: 31471636]
  63. Carroll P, Goldstein GD, Brown CW Jr. (2000) Metastatic microcystic adnexal carcinoma in an immunocompromised patient. Dermatol Surg 26:531–534 [PMID: 10848932]
  64. Rütten A (2018) Tumoren der Hautadnexe. In: Plewig G, Ruzicka T, Kaufmann R, Hertl M (Hrsg) Braun-Falco’s Dermatologie, Venerologie und Allergologie. Springer Reference Medizin. Springer, Berlin, Heidelberg https://doi.org/10.1007/978-3-662-49544-5_10 [DOI: 10.1007/978-3-662-49544-5_10]

MeSH Term

Adenocarcinoma, Sebaceous
Humans
Sebaceous Gland Neoplasms
Skin
Skin Neoplasms
Sweat Gland Neoplasms
Journal Article

Word Cloud

Created with Highcharts 10.0.0adnexalneoplasmssebaceouscarcinomaMalignantskina heterogeneousgroupraremalignancieseccrineapocrinefolliculardifferentiationEssentialclinicalpracticerecommendationsoverallmanagementcancerspresentedMoreoverspecificevidence-basedfindingsaccordingdiagnosistherapyfollow-upporocarcinomamicrocysticadnexcarcinomawillexplained[Managementmalignantskin]HistopathologyMalignancyMicrocysticPorocarcinomaSebaceousgland

Similar Articles

Cited By

No available data.